This is not about the Blackberry. A conspiracy-theory laden report in the BBC tells how the US sweetener (corn?) industry manipulated the FDA to crush competition:
Legal advice and contact with the FDA had led Harvey to believe that the extract from the berry would be allowed under the classification “generally recognised as safe”. Having been eaten for centuries in Africa, without anecdotal reports of problems, it could be assumed not to be harmful.
But the FDA decided it would be considered as an additive which required several years more testing. In the poor economic climate of 1974, this could not be funded and the company folded.
“I was in shock,” says Harvey. “We were on very good terms with the FDA and enjoyed their full support. There was no sign of any problem. Without any opportunity to know what the concern was and who raised it, and to respond to it – they just banned the product.”
One might also suspect Harvey was naive, or there was a general lack of planning on his part, or his financial backers threw in the towel. However, other aspects of the story suggest industrial interference played a role.
A car was spotted driving back and forwards past Miralin’s offices, slowing down as someone took photographs of the building. Then, late one night, Harvey was followed as he drove home.
“I sped up, then he sped up. I pulled into this dirt access road and turned off my lights and the other car went past the end of the road at a very high speed. Clearly I was being monitored.”
Finally, at the end of that summer, Harvey and Emery arrived back at the office after dinner to find they were being burgled. The burglars escaped and were never found, but the main FDA file was left lying open on the floor.
A few weeks later the FDA, which had previously been very supportive, wrote to Miralin, effectively banning its product. No co-incidence, according to Don Emery.
“I honestly believe that we were done in by some industrial interest that did not want to see us survive because we were a threat. Somebody influenced somebody in the FDA to cause the regulatory action that was taken against us.”
All questions of “if you suspected foul play why didn’t you plan to defend yourself” aside, I have to wonder why it was only a product marketed for the US. Barclays was a backer, so surely they were aware of market options in Europe, let alone Asia.